Objectives: The Centers for Medicare & Medicaid Services does not explicitly use cost-effectiveness information in national coverage determinations. The objective of this study was to illustrate potential efficiency gains from reallocating Medicare expenditures by using cost-effectiveness information, and the consequences for health gains among Medicare beneficiaries. Methods: We included national coverage determinations from 1999 through 2007. Estimates of costeffectiveness were identified through a literature review. For coverage decisions with an associated cost-effectiveness estimate, we estimated utilization and size of the ''unserved'' eligible population by using a Medicare claims database (2007) and diagnostic and reimbursement codes. Technology costs originated from the costeffectiveness literature or were estimated by using reimbursement codes. We illustrated potential aggregate health gains from increasing utilization of dominant interventions (i.e., cost saving and health increasing) and from reallocating expenditures by decreasing investment in cost-ineffective interventions and increasing investment in relatively cost-effective interventions. Results: Complete information was available for 36 interventions. Increasing investment in dominant interventions alone led to an increase of 270,000 quality-adjusted lifeyears (QALYs) and savings of $12.9 billion. Reallocation of a broader array of interventions yielded an additional 1.8 million QALYs, approximately 0.17 QALYs per affected Medicare beneficiary. Compared with the distribution of resources prior to reallocation, following reallocation a greater proportion was directed to oncology, diagnostic imaging/tests, and the most prevalent diseases. A smaller proportion of resources went to cardiology, treatments (including drugs, surgeries, and medical devices, as opposed to nontreatments such as preventive services), and the least prevalent diseases. Conclusions: Using cost-effectiveness information has the potential to increase the aggregate health of Medicare beneficiaries while maintaining existing spending levels.
Introduction
It is well documented that US health care spending growth is unsustainable [1, 2] . Compared with other developed countries, return on health care spending in the United States is poor, with a significant proportion of the American population lacking health insurance and the health care system performing poorly across key metrics such as life expectancy and infant mortality [3] . In many countries, cost-effectiveness analysis is used to prioritize scarce health care resources among competing interventions. Despite the immediate need to increase the value of health care spending, however, decision makers in the United States have resisted this approach [4] .
More than 46 million Americans, including those 65 years and older and those with certain disabilities, receive health insurance through Medicare. The Centers for Medicare & Medicaid Services (CMS) does not operate with a fixed budget, and program cost has increased annually at a relatively rapid rate. The program's current annual cost is estimated at upwards of $600 billion, approximately 3.5% of the gross domestic product, and may reach $1 trillion by 2020 [5] . Research indicates that approximately 30% of Medicare spending may be inappropriate or unnecessary [6] [7] [8] [9] [10] .
The CMS issues approximately 10 to 15 national coverage determinations (NCDs) each year for interventions deemed to have a significant impact on the Medicare program [11] . With respect to cost-effectiveness evidence, CMS states that it ''is not a factor CMS considers in making NCDs'' [12] . While research suggests that coverage decisions made in NCDs are broadly consistent with cost-effectiveness evidence-that is, technologies associated with favorable cost-effectiveness estimates tend to be covered-a number of covered interventions are not costeffective by traditional standards, with incremental cost-effectiveness ratios (ICERs) greater than $250k per quality-adjusted life-year (QALY) gained [13] . Thus, efficiency gains are possible through disinvestments in cost-ineffective interventions and investments in relatively cost-effective interventions.
The objective of this research was to estimate potential aggregate health gains from increasing utilization of dominant (i.e., cost-saving and health increasing) interventions, and from a hypothetical reallocation of expenditures among interventions subject to NCDs, through the use of a cost-effectiveness decision rule. We also sought to estimate the impact of reallocation on the distribution of expenditures across diseases and types of intervention. We acknowledge that this is an illustrative exercise, but we believe that it is important as the first of its kind to demonstrate the consequences of using cost-effectiveness information to inform resource allocation. We highlight the research challenges, particularly with regards to data limitations.
Methods

National Coverage Determinations
We created a database of NCDs issued by the CMS from 1999 through 2007. We excluded incomplete NCDs or those pertaining to minor coding or language changes, as well as those pertaining to off-label treatments, coverage in clinical trials, coverage with evidence development policies, or treatment facilities. Frequently, NCDs include multiple coverage decisions, often for different interventions or patient populations. Furthermore, on occasion coverage is permitted only for patient subgroups that meet certain conditions and restrictions. An entry was made in the database for each separate coverage decision implied within each NCD. We have previously used this database to evaluate factors that predict positive CMS coverage decisions for interventions [14] .
Reallocation of Expenditures
To facilitate our analysis, we limited our sample to NCDs in which we could find available estimates of: cost-effectiveness; incremental cost; cost of intervention and comparator in the first year of use; incremental health gain; number of Medicare beneficiaries currently receiving the intervention; and the size of the unserved patient population, that is, Medicare beneficiaries who were eligible for the intervention but did not receive it. Each parameter will be discussed further.
Cost-Effectiveness
On occasion we were able to identify the cost-effectiveness estimate from CMS's decision memo, which comprises the agency's public communication about the NCD, including the evidence featured in its review. In the majority of the cases, we identified cost-effectiveness evidence through a literature search by using the PubMed database, the Tufts Medical Center Cost-Effectiveness Analysis Registry, the Health Economic Evaluations Database, and the National Health Service Economic Evaluation Database [15] [16] [17] [18] . The findings of the literature search have been published elsewhere [13] . Most frequently, the reported ICER was in the form of a cost per QALY gained. On occasion, the ICER was presented in the form of a cost per life-year (LY) gained, and we adjusted incremental survival gain with a utility weight for Americans aged 65 to 69 years to create an estimate of incremental QALY gained [19] . This adjustment may underestimate the incremental QALY gain as only the years of life extended by the treatment (incremental LYs gained) are accounted for when adjusting for quality of life, not prior years of treatment during which patient quality of life may have been improved. In sensitivity analyses, we included cost-effectiveness studies that estimated the intervention to be ''dominant''-that is, more effective and less costly than the comparator-even if the study reported health outcome using disease-specific units, for example, tumors detected, rather than QALYs or LYs. The majority of costeffectiveness studies were performed in a US health care system setting (26 of 34, 67%), and of those 63% (15 of 26) incorporated Medicare costs. Occasionally, a US study was unavailable and we included a non-US study. In these instances, we converted the ICER into US dollars by using purchasing power parities, and indexed to the year the coverage decision was made by using the health component of the consumer price index [20, 21] .
Utilization Rate-Served and Unserved Population
We estimated intervention utilization rates by using a database of Medicare inpatient and outpatient claims [22] . We used International Classification of Diseases, Ninth Revision (ICD-9) diagnostic codes reported in the database to identify Medicare beneficiaries eligible for an intervention, as defined by the parameters of the NCD. The database also includes Common Procedural Terminology (CPT) codes used for physician reimbursement. We estimated utilization rates by calculating the number of beneficiaries who had matching relevant ICD-9 diagnostic and CPT codes. We estimated the size of the unserved eligible population by calculating the difference between the number of beneficiaries who were a match for both ICD-9 diagnostic and CPT codes and those who were a match solely with ICD-9 diagnostic codes.
Incremental Cost Data
We extracted incremental cost data, that is, the net present value of future expenditures (the numerator of the ICER), from the included cost-effectiveness study, and when necessary adjusted it to 2007 USDs.
Cost of Intervention and Comparator in First Year of Use
We included the cost of the intervention and the comparator in the first year of use when it was reported in the cost-effectiveness study (64% of cases). When not reported, we estimated the cost of the intervention and the comparator in the year following first use from Medicare and physician reimbursement codes (36% of cases). Pertinent reimbursement codes were identified from Medicare documentation, the included cost-effectiveness study, or the manufacturer's website. For interventions subject to noncoverage decisions, we obtained the relevant information from the cost-effectiveness study.
Categorization of Interventions
To analyze the effect of the reallocation exercise on the distribution of expenditures, we categorized interventions with respect to disease (cardiology, oncology, and other), type of intervention (treatment, diagnostic, and other, i.e., education, preventative care, and mobility assistive equipment), and size of the eligible population (41 million beneficiaries, 50,000-1 million beneficiaries, and o50,000 beneficiaries).
Reallocation of Expenditures
In the first analysis, we illustrated the effects of increasing the utilization of dominant interventions, while maintaining the existing utilization of nondominant interventions. That is, for dominant interventions we decreased by 50% the size of the unserved population, that is, Medicare beneficiaries who were eligible for the intervention but did not receive it. We assumed a 50% shift for the reallocation, reasoning that shifting all beneficiaries from one intervention to another would be infeasible in practice. To illustrate the possible range of aggregate health gains, we repeated this analysis by adjusting utilization by 10% and 90%, respectively.
In the second analysis, we reallocated existing resources by using an iterative process. First, we ranked interventions in order of cost-effectiveness. Second, to generate resources for investment in more cost-effective interventions, we ''disinvested'' in the least cost-effective intervention. Disinvestment was achieved by reducing the existing utilization of the least cost-effective intervention by 50%. Third, with the resources generated from the disinvestment, we increased investment in the most cost-effective intervention. This was achieved by decreasing the size of the unserved eligible population by up to 50%. We continued this process by repeating the second and third steps, that is, disinvesting in the next least cost-effective intervention and investing in the next most cost-effective intervention, until no further reallocation of expenditures was possible and there was no net change in expenditure. We also repeated this analysis by adjusting utilization by 10% and 90%, respectively. Finally, we compared the existing and ''ideal'' distributions of resources across indications, types of technology, and conditions of different prevalence.
Assumptions
The reallocation exercise adhered to the assumptions necessary for the league table approach described by Johannesson and Weinstein [23] : perfect divisibility; that is, a partially implemented health care program will maintain the characteristics of the entire program; and constant returns to scale; that is, costs and effects are proportional to the scale of implementation. Our analysis required additional assumptions. First, all Medicare beneficiaries eligible for care, as defined by the parameters of the NCD, received an intervention. Second, the comparator included in the cost-effectiveness study was the alternative intervention received in all cases. Third, we ordered interventions by using the net present value of their total costs (including downstream costs) and assumed that for interventions with a high upfront cost, for example, surgeries, resources were available to fund that ''initial investment.'' Figure 1 shows the process by which we arrived at the final sample of interventions. Thirty-six of 64 interventions associated with an estimate of cost-effectiveness were included (Table 1) . Twenty-six of the 28 excluded interventions were removed because of incomplete data, for which the most common reason was our inability to accurately identify the utilization rate for the intervention in the indicated patient population. For example, for ultrasound stimulation for nonunion fracture healing, no beneficiaries had a combination of the necessary ICD-9 codes, that is, ICD-9 code for nonunion fracture healing (733.82) and for fractures of the relevant bones (tibial [823], scaphoid [814], and radius [813]). We excluded two interventions because they were dominated by another intervention in the sample.
Results
We included both positive and noncoverage decisions included in NCDs made from 1999 through 2007. Of the 36 coverage decisions, 29 (81%) were positive and 7 (19%) were noncoverage decisions. We included noncoverage decisions to maximize the sample size and to evaluate the consequences of reallocation when using cost-effectiveness evidence as the sole criterion for resource allocation. While our previous research has demonstrated that covered technologies tend to be more cost-effective than noncovered ones, this was not necessarily the case for the technologies included here [13] . Indeed, the least cost-effective technologies in our sample were covered, while noncovered technologies were typically associated with favorable ICERs (e.g., the noncovered intervention acupuncture for osteoarthritis had a reported ICER (Table 1) . For the first analysis, increasing utilization of dominant interventions had a substantial impact on aggregate health gain and cost-savings. When we considered the net present value of future commitments, and included dominant interventions without an estimate of incremental QALY gain, increasing the utilization of dominant interventions while maintaining the existing utilization of interventions associated with a positive ICER resulted in an additional 5.5 million beneficiaries receiving the most effective intervention, an additional 0.27 million QALYs gained, and approximately $12.9 billion of cost-savings ( Table 2) .
For the second analysis, when we considered the net present value of future commitments and included dominant interventions without an estimate of incremental QALY gain, reallocation of expenditures resulted in an additional 11.1 million beneficiaries receiving the most effective intervention ( Table 2) . This corresponded to an additional 1.86 million QALYs, approximately 0.17 QALYs per beneficiary affected by the reallocation. The ICER of the marginal technology, that is, the least cost-effective intervention for which utilization was increased, was approximately $18,000 per QALY (bariatric surgery for the treatment of morbid obesity). When we reallocated expenditures in the year following the first use of the intervention, the findings were similar, although the magnitude of changes was smaller. The ICER of the marginal technology was approximately $3,300 per QALY (external counterpulsation therapy).
When we considered only interventions with an available estimate of incremental QALY gain, 25 interventions were included in the reallocation. Findings were broadly consistent with the analysis including interventions without a QALY gain estimate, although the magnitude of gain was smaller ( Table 2) .
The reallocation had a notable impact on the distribution of expenditures across diseases (Table 3) . Following reallocation, a greater proportion of expenditures was directed to beneficiaries receiving an oncology-related intervention (approximately 43%), for example, positron emission tomography for various cancers. In contrast, a decreased proportion was directed to those receiving a cardiology-related intervention (approximately 34%), for example, implantable cardioverter defibrillators. Furthermore, a decreased proportion was directed to interventions categorized as other (approximately 24%), for example, warm-up wound therapy for ulcers. With respect to intervention type, following reallocation the proportion of beneficiaries receiving an intervention categorized as treatment, for example, ocular photodynamic therapy with verteporfin for macular degeneration, or diagnostic, for example, screening immunoassay fecal-occult blood test for colorectal cancer, increased (approximately 50% and 44%, respectively), while the proportion of beneficiaries receiving interventions categorized as other, for example, foot care for diabetic peripheral neuropathy with loss of protective sensation, decreased (approximately 7%). Following reallocation, a much greater proportion of expenditures was directed to beneficiaries receiving interventions with an eligible population of more than 1 million beneficiaries (approximately 78%), for example, external counterpulsation therapy, while a decreased proportion was directed to beneficiaries receiving an intervention with an eligible population of 50,000 to 1 million beneficiaries (approximately 22%), for example, cardiac rehabilitation programs for acute myocardial infarction and percutaneous transluminal coronary angioplasty, and less than 50,000 beneficiaries (0.2%), for example, intravenous immune globulin for bullous pemphigoid, respectively. (10%-90%), and investment in relatively cost-effective interventions, achieved by decreasing the size of the unserved eligible population, i.e., Medicare beneficiaries who were eligible for the intervention but who did not receive it, by up to 50% (10%-90%).
Discussion
Coverage of cost-ineffective interventions generates relatively little health gain for the expenditure and suggests that existing resources could provide greater benefits if directed toward more cost-effective alternative interventions. As others have shown, using cost-effectiveness evidence can lead to more efficient resource allocation [24] . For this research we used an empirical approach to estimate efficiency gains by reallocating expenditures among interventions considered in NCDs by using a costeffectiveness decision rule. This approach differs from studies that highlight inefficiencies by comparing expenditures across jurisdictions when adjusting for differences in populations [25, 26] . While these studies highlight opportunities for efficiency gains, they do not suggest an approach to making care more efficient. In contrast, this study illustrates the potential to increase the aggregate health of Medicare beneficiaries while maintaining existing spending levels. Our findings suggest that substantial efficiency gains are achievable by reallocating expenditures in accordance with cost-effectiveness evidence. Simply increasing the utilization of dominant interventions increases aggregate health gain, while generating addition resources, an approach in which no patients would receive a less effective therapeutic option. Reallocating expenditures in accordance with a broader definition of the costeffectiveness evidence increases the number of beneficiaries receiving the most effective therapeutic option-though inevitably some patients would then receive a less effective option than their current therapy-and results in sizeable aggregate health gains. As we included dominant interventions without an estimate of incremental QALY gain in the analysis, aggregate population health gain estimates are likely conservative.
Reallocation also affects the distribution of expenditures across diseases. Following reallocation, a greater proportion of resources was directed to beneficiaries receiving oncology-related interventions and a lesser proportion to beneficiaries receiving cardiology-related interventions and diseases categorized as other. Interestingly, many cost-effective, oncology-related interventions in our sample were diagnostic imaging modalities (e.g., positron emission tomography for various cancers) and tests, rather than chemotherapies, which are often associated with high ICERs [27] .
Limitations and Challenges
Many of the challenges of this research pertain to data limitations. Unlike other health technology assessment agencies-for example, the National Institute of Health and Clinical Excellence in the United Kingdom-the CMS does not independently perform cost-effectiveness analyses, nor does it require submission of cost-effectiveness evidence. Consequently, few of the costeffectiveness estimates we used originated from CMS decision memos, and for the most part we relied on estimates identified in the cost-effectiveness literature. As a result, there may have been a lack of consistency among cost-effectiveness studies with respect to methodology, perspective, costing, country of study, and so on.
While necessary, we used ICD-9 diagnostic codes to identify eligible beneficiaries, though this approach was somewhat crude, as such codes do not sufficiently capture all factors that inform patient management in practice, for example, patient preference. The Medicare claims database provides a ''snapshot'' of interventions received by Medicare beneficiaries and does not distinguish between incident and prevalent cases. Without this information, identifying eligible beneficiaries is imprecise; for example, identifying a beneficiary with Parkinson's disease is insufficient to confirm his or her eligibility for deep brain stimulation, as this treatment is indicated only once pharmaceutical management is no longer effective. For other interventions, this is less problematic (e.g., foot care for diabetic patients suffering from diabetic peripheral neuropathy with loss of protective sensation), as the ICD-9 diagnostic codes were sufficient to identify this patient population.
An important assumption was that eligible patients who did not receive the intervention instead received the study comparator. While we attempted to ensure that CMS deemed the comparator relevant by affirming that CMS discussed it in the decision memo, this assumption introduces potential bias. In many cases, despite eligibility, Medicare beneficiaries are likely to receive no therapy or an alternative therapy not included in the cost-effectiveness analysis. Thus, there is potential for the ICER to be either overestimated or underestimated. In future research, we plan to explore and try to validate this assumption, potentially utilizing clinical opinion.
The requirement to integrate data from various sources limits the accuracy of study findings. Indeed, our study highlights the challenges of using currently available data for this type of analysis. While US-based recommendations for the performance cost-effectiveness analyses exist, evidence suggests that they are followed inconsistently [28] .
Policy Significance and Next Steps
In the United States, cost-effectiveness is often conflated with ''rationing'' and a reduction in health care provision. This research shows that rather than using it to reduce spending, it can identify how to increase aggregate population health while maintaining existing spending levels. Despite the limited number of considered interventions, our analysis illustrated that an additional 1.86 million QALYs (0.17 QALYs per affected beneficiary) were achievable, suggesting substantial gains in aggregate health if the policy were implemented on a larger scale.
The least cost-effective intervention to which more expenditure was allocated after reallocation was associated with an ICER of $18,000 per QALY (bariatric surgery for the treatment of morbid obesity), less than the often used benchmarks of value in the United States, for example, $50,000 to $100,000 per QALY [29] . This finding suggests that there is much potential for Medicare to increase spending on interventions associated with ICERs judged highly cost-effective by traditional standards, while reducing spending on interventions deemed comparatively cost-ineffective [30] .
Our research is not offered as a precise accounting exercise, but rather as an illustration of the potential of this approach, which, while incorporating a number of assumptions, underscores the substantial aggregate health gains potentially achievable from using cost-effectiveness evidence to inform resource allocation. Indeed, gains may be even greater if one could better account for patient heterogeneity and if beneficiaries who would benefit most were prioritized for treatment.
For a number of included dominant interventions, positive expenditure was required in their first year of use, with aggregate cost-savings achieved in subsequent years, for example, foot care for diabetic patients with neuropathy. This finding emphasizes that considering interventions over a short time horizon may not adequately account for the potential positive financial impact on the entire health care system. The apparent underutilization of dominant interventions provides an opportunity for policymakers. Research suggests that underutilization may be due to a lack of physician referral, insufficient physician reimbursement, and perceived clinical benefits of the intervention, among other factors [31] [32] [33] .
Ideally, data available for the research in this article would be more abundant, and of higher quality and greater consistency. Preferably, available cost-effectiveness studies would include Medicare-specific direct costs and account for all relevant competing interventions. Costs would meet the specifications necessary to facilitate potential legislative action, for example, meet the standards of the Congressional Budget Office and CMS's Office of the Actuary [34, 35] . Technologies should be evaluated over a time horizon for which costs and consequences, in terms of QALYs, are likely to differ, and reported on an annual basis. Ideally, studies would account for patient heterogeneity, with data available on the effectiveness of the intervention across beneficiaries in the indicated population.
Using a cost-effectiveness decision rule for resource allocation will impact the distribution of resources across Medicare beneficiaries. Despite the small number of included coverage decisions, the findings underscore the trade-offs inherent in resource allocation decisions, for example, the opportunity cost of prioritizing resources to a particular patient group. Indeed, the objective of maximizing aggregate health subject to a budget constraint is not entirely consistent with CMS's decision-making criteria. Other factors including the nature, strength, and uncertainty of the available evidence; the availability of alternative interventions; potential impact of the decision on access to health care; statutory mandates to cover certain services; and political considerations are important as well [36, 37] .
It is important to highlight that a minority of CMS's coverage decisions for interventions are made at the national level in NCDs and that we included only coverage decisions associated with cost-effectiveness estimates. Consequently, this research is limited to a relatively small, and potentially unrepresentative, selection of interventions. Included interventions may not be those for which a reallocation of expenditures would yield the greatest efficiency gains. Indeed, targeting interventions with the largest potential health gains may be impractical if they reflect widely used and accepted services, despite poor costeffectiveness. Rather, targeting interventions for which a change in therapeutic management is more feasible may be a more appropriate approach. We chose arbitrarily to use a 50% (range 10%-90%) change in utilization to simulate resource allocation. Accounting for the relative ease of investing/disinvesting in interventions would be one approach for advancing this research and may produce more realistic efficiency gain estimates.
As an illustrative exercise this research could be furthered by focusing on a select group of interventions for which high-quality data are available, potentially interventions from the same class or for the same indication. Having data of sufficient quality would allow the adoption of alternative approaches, for example, integer programming, or a stochastic process to account for uncertainty in the parameter estimates and for disease incidence.
A larger sample would allow a more comprehensive categorization of interventions and facilitate a more thorough examination of the consequences of using cost-effectiveness evidence to guide resource allocation. For example, as research has shown that society has a preference for the treatment of severe diseases, a variable to capture disease severity would be valuable [38] [39] [40] [41] . By better understanding Medicare beneficiaries' resource allocation preferences, the appropriateness of alternative resource use patterns could be evaluated.
Conclusions
While the US health care system has not embraced the use of cost-effectiveness evidence to inform health care resource allocation, this research illustrates the potential value and consequences of such an approach. While it is apparent that available data present challenges with this methodology, our research illustrates that substantial health gains are achievable from a reallocation of expenditures within existing spending levels.
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